Citigroup Downgrades Apogee Therapeutics to Neutral, Raises Price Target to $135

Benzinga Newsdesk www.benzinga.com Negative 41.3%

Neg 41.3% Neu 0% Pos 0%

Citigroup analyst Geoff Meacham downgrades Apogee Therapeutics (NASDAQ:APGE) from Buy to Neutral and raises the price target from $125 to $135.